Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome.
Expert Opin Pharmacother
; 23(3): 349-360, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1516492
ABSTRACT
INTRODUCTION:
Noninvasive mechanical ventilation is the main supportive measure used in patients with pediatric ARDS (PARDS), but adjunctive pharmacological therapies (corticosteroids, inhaled nitric oxide [iNO], surfactant replacement therapy and neuromuscular blocking drugs) are also used, although limited data exists to inform of this practice. AREAS COVERED The authors review the current challenges in the pharmacological management of PARDS and highlight the few certainties currently available. EXPERT OPINION Children with PARDS must not be treated as young adults with ARDS, essentially because children's lungs differ substantially from those of adults and PARDS occurs in children differently than ARDS in adults. Pharmacological treatments available for PARDS are relatively few and, since there is great uncertainty about their effectiveness also because of the extreme heterogeneity of this syndrome, it is necessary to conduct large clinical trials using currently available definitions and considering recent pathobiological knowledge. The aim is to identify homogeneous subgroups or phenotypes of children with PARDS that may benefit from the specific pharmaceutical approach examined. It will be then necessary to link endotypes and outcomes to appropriately target therapies in future trials, but this will be possible only after it will be possible to identify the different PARDS endotypes.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Graft vs Host Disease
Type of study:
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Expert Opin Pharmacother
Journal subject:
Pharmacology
Year:
2022
Document Type:
Article
Affiliation country:
14656566.2021.2006632
Similar
MEDLINE
...
LILACS
LIS